| DS N = 12 . | ADRNP N = 54 . | |
|---|---|---|
| Pathology data | ||
| Postmortem interval, h | 10.5 ± 8.7 | 8.7 ± 5.5 |
| Fresh brain weight, g | 1073.7 ± 252.0 | 1164.0 ± 166.9 |
| ADNC, n (%) | ||
| None | – | 2 (4%) |
| Low | – | 5 (9%) |
| Intermediate | 5 (42%) | 13 (24%) |
| High | 7 (58%) | 34 (63%) |
| Thal phase | ||
| 0 | – | 2 (4%) |
| 1 | – | 4 (7%) |
| 2 | 3 (25%) | 1 (2%) |
| 3 | 2 (17%) | 9 (17%) |
| 4 | 2 (17%) | 5 (9%) |
| 5 | 5 (42%) | 33 (61%) |
| Braak NFT stage | ||
| 0 | – | 1 (2%) |
| 1 | – | 2 (4%) |
| 2 | – | 2 (4%) |
| 3 | – | 7 (13%) |
| 4 | 2 (17%) | 7 (13%) |
| 5 | 2 (17%) | 12 (22%) |
| 6 | 8 (66%) | 23 (43%) |
| C score | ||
| 0 | – | 6 (11%) |
| 1 | – | – |
| 2 | 3 (25%) | 14 (26%) |
| 3 | 9 (75%) | 34 (63%) |
| LATE-NC stage | ||
| 0 | 10 (83%) | 31 (57%) |
| 1 | – | 6 (11%) |
| 2 | 2 (17%) | 17 (32%) |
| HS | ||
| Absent | 10 (83%) | 45 (83%) |
| Present | 2 (17%) | 9 (17%) |
| Lewy body stage | ||
| 0 | 8 (66%) | 19 (35%) |
| 1 = olfactory or brainstem | – | 7 (13%) |
| 2 = amygdala | 2 (17%) | 10 (18%) |
| 3 = limbic | – | 8 (15%) |
| 4 = neocortical | 2 (17%) | 10 (18%) |
| Arteriolosclerosis | ||
| 0 = none | 1 (8%) | 3 (6%) |
| 1 = mild | 7 (58%) | 27 (50%) |
| 2 = moderate | 4 (33%) | 13 (24%) |
| 3 = severe | – | 11 (20%) |
| Atherosclerosis | ||
| 0 = none | 6 (50%) | 17 (32%) |
| 1 = mild | – | 22 (41%) |
| 2 = moderate | – | 12 (22%) |
| 3 = severe | – | 3 (6%) |
| Not assessed | 6 (50%) | – |
| Cerebral amyloid angiopathy | ||
| 0 = none | 1 (8%) | 6 (11%) |
| 1 = mild | 2 (17%) | 30 (56%) |
| 2 = moderate | 4 (33%) | 10 (19%) |
| 3 = severe | 5 (42%) | 8 (15%) |
| DS N = 12 . | ADRNP N = 54 . | |
|---|---|---|
| Pathology data | ||
| Postmortem interval, h | 10.5 ± 8.7 | 8.7 ± 5.5 |
| Fresh brain weight, g | 1073.7 ± 252.0 | 1164.0 ± 166.9 |
| ADNC, n (%) | ||
| None | – | 2 (4%) |
| Low | – | 5 (9%) |
| Intermediate | 5 (42%) | 13 (24%) |
| High | 7 (58%) | 34 (63%) |
| Thal phase | ||
| 0 | – | 2 (4%) |
| 1 | – | 4 (7%) |
| 2 | 3 (25%) | 1 (2%) |
| 3 | 2 (17%) | 9 (17%) |
| 4 | 2 (17%) | 5 (9%) |
| 5 | 5 (42%) | 33 (61%) |
| Braak NFT stage | ||
| 0 | – | 1 (2%) |
| 1 | – | 2 (4%) |
| 2 | – | 2 (4%) |
| 3 | – | 7 (13%) |
| 4 | 2 (17%) | 7 (13%) |
| 5 | 2 (17%) | 12 (22%) |
| 6 | 8 (66%) | 23 (43%) |
| C score | ||
| 0 | – | 6 (11%) |
| 1 | – | – |
| 2 | 3 (25%) | 14 (26%) |
| 3 | 9 (75%) | 34 (63%) |
| LATE-NC stage | ||
| 0 | 10 (83%) | 31 (57%) |
| 1 | – | 6 (11%) |
| 2 | 2 (17%) | 17 (32%) |
| HS | ||
| Absent | 10 (83%) | 45 (83%) |
| Present | 2 (17%) | 9 (17%) |
| Lewy body stage | ||
| 0 | 8 (66%) | 19 (35%) |
| 1 = olfactory or brainstem | – | 7 (13%) |
| 2 = amygdala | 2 (17%) | 10 (18%) |
| 3 = limbic | – | 8 (15%) |
| 4 = neocortical | 2 (17%) | 10 (18%) |
| Arteriolosclerosis | ||
| 0 = none | 1 (8%) | 3 (6%) |
| 1 = mild | 7 (58%) | 27 (50%) |
| 2 = moderate | 4 (33%) | 13 (24%) |
| 3 = severe | – | 11 (20%) |
| Atherosclerosis | ||
| 0 = none | 6 (50%) | 17 (32%) |
| 1 = mild | – | 22 (41%) |
| 2 = moderate | – | 12 (22%) |
| 3 = severe | – | 3 (6%) |
| Not assessed | 6 (50%) | – |
| Cerebral amyloid angiopathy | ||
| 0 = none | 1 (8%) | 6 (11%) |
| 1 = mild | 2 (17%) | 30 (56%) |
| 2 = moderate | 4 (33%) | 10 (19%) |
| 3 = severe | 5 (42%) | 8 (15%) |
Abbreviations: ADNC, Alzheimer’s disease neuropathologic change; HS, hippocampal sclerosis; NFT, neurofibrillary tangle; LATE-NC, limbic-predominant age-related TDP-43 encephalopathy neuropathologic change.
| DS N = 12 . | ADRNP N = 54 . | |
|---|---|---|
| Pathology data | ||
| Postmortem interval, h | 10.5 ± 8.7 | 8.7 ± 5.5 |
| Fresh brain weight, g | 1073.7 ± 252.0 | 1164.0 ± 166.9 |
| ADNC, n (%) | ||
| None | – | 2 (4%) |
| Low | – | 5 (9%) |
| Intermediate | 5 (42%) | 13 (24%) |
| High | 7 (58%) | 34 (63%) |
| Thal phase | ||
| 0 | – | 2 (4%) |
| 1 | – | 4 (7%) |
| 2 | 3 (25%) | 1 (2%) |
| 3 | 2 (17%) | 9 (17%) |
| 4 | 2 (17%) | 5 (9%) |
| 5 | 5 (42%) | 33 (61%) |
| Braak NFT stage | ||
| 0 | – | 1 (2%) |
| 1 | – | 2 (4%) |
| 2 | – | 2 (4%) |
| 3 | – | 7 (13%) |
| 4 | 2 (17%) | 7 (13%) |
| 5 | 2 (17%) | 12 (22%) |
| 6 | 8 (66%) | 23 (43%) |
| C score | ||
| 0 | – | 6 (11%) |
| 1 | – | – |
| 2 | 3 (25%) | 14 (26%) |
| 3 | 9 (75%) | 34 (63%) |
| LATE-NC stage | ||
| 0 | 10 (83%) | 31 (57%) |
| 1 | – | 6 (11%) |
| 2 | 2 (17%) | 17 (32%) |
| HS | ||
| Absent | 10 (83%) | 45 (83%) |
| Present | 2 (17%) | 9 (17%) |
| Lewy body stage | ||
| 0 | 8 (66%) | 19 (35%) |
| 1 = olfactory or brainstem | – | 7 (13%) |
| 2 = amygdala | 2 (17%) | 10 (18%) |
| 3 = limbic | – | 8 (15%) |
| 4 = neocortical | 2 (17%) | 10 (18%) |
| Arteriolosclerosis | ||
| 0 = none | 1 (8%) | 3 (6%) |
| 1 = mild | 7 (58%) | 27 (50%) |
| 2 = moderate | 4 (33%) | 13 (24%) |
| 3 = severe | – | 11 (20%) |
| Atherosclerosis | ||
| 0 = none | 6 (50%) | 17 (32%) |
| 1 = mild | – | 22 (41%) |
| 2 = moderate | – | 12 (22%) |
| 3 = severe | – | 3 (6%) |
| Not assessed | 6 (50%) | – |
| Cerebral amyloid angiopathy | ||
| 0 = none | 1 (8%) | 6 (11%) |
| 1 = mild | 2 (17%) | 30 (56%) |
| 2 = moderate | 4 (33%) | 10 (19%) |
| 3 = severe | 5 (42%) | 8 (15%) |
| DS N = 12 . | ADRNP N = 54 . | |
|---|---|---|
| Pathology data | ||
| Postmortem interval, h | 10.5 ± 8.7 | 8.7 ± 5.5 |
| Fresh brain weight, g | 1073.7 ± 252.0 | 1164.0 ± 166.9 |
| ADNC, n (%) | ||
| None | – | 2 (4%) |
| Low | – | 5 (9%) |
| Intermediate | 5 (42%) | 13 (24%) |
| High | 7 (58%) | 34 (63%) |
| Thal phase | ||
| 0 | – | 2 (4%) |
| 1 | – | 4 (7%) |
| 2 | 3 (25%) | 1 (2%) |
| 3 | 2 (17%) | 9 (17%) |
| 4 | 2 (17%) | 5 (9%) |
| 5 | 5 (42%) | 33 (61%) |
| Braak NFT stage | ||
| 0 | – | 1 (2%) |
| 1 | – | 2 (4%) |
| 2 | – | 2 (4%) |
| 3 | – | 7 (13%) |
| 4 | 2 (17%) | 7 (13%) |
| 5 | 2 (17%) | 12 (22%) |
| 6 | 8 (66%) | 23 (43%) |
| C score | ||
| 0 | – | 6 (11%) |
| 1 | – | – |
| 2 | 3 (25%) | 14 (26%) |
| 3 | 9 (75%) | 34 (63%) |
| LATE-NC stage | ||
| 0 | 10 (83%) | 31 (57%) |
| 1 | – | 6 (11%) |
| 2 | 2 (17%) | 17 (32%) |
| HS | ||
| Absent | 10 (83%) | 45 (83%) |
| Present | 2 (17%) | 9 (17%) |
| Lewy body stage | ||
| 0 | 8 (66%) | 19 (35%) |
| 1 = olfactory or brainstem | – | 7 (13%) |
| 2 = amygdala | 2 (17%) | 10 (18%) |
| 3 = limbic | – | 8 (15%) |
| 4 = neocortical | 2 (17%) | 10 (18%) |
| Arteriolosclerosis | ||
| 0 = none | 1 (8%) | 3 (6%) |
| 1 = mild | 7 (58%) | 27 (50%) |
| 2 = moderate | 4 (33%) | 13 (24%) |
| 3 = severe | – | 11 (20%) |
| Atherosclerosis | ||
| 0 = none | 6 (50%) | 17 (32%) |
| 1 = mild | – | 22 (41%) |
| 2 = moderate | – | 12 (22%) |
| 3 = severe | – | 3 (6%) |
| Not assessed | 6 (50%) | – |
| Cerebral amyloid angiopathy | ||
| 0 = none | 1 (8%) | 6 (11%) |
| 1 = mild | 2 (17%) | 30 (56%) |
| 2 = moderate | 4 (33%) | 10 (19%) |
| 3 = severe | 5 (42%) | 8 (15%) |
Abbreviations: ADNC, Alzheimer’s disease neuropathologic change; HS, hippocampal sclerosis; NFT, neurofibrillary tangle; LATE-NC, limbic-predominant age-related TDP-43 encephalopathy neuropathologic change.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
